Results 21 to 30 of about 265,672 (255)

MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells

OncoImmunology, 2023
Natural Killer (NK) cells are important components of the immune system in the defense against tumor growth and metastasis. They release exosomes containing proteins and nucleic acids, including microRNAs (miRNAs).
Anna Laura Di Pace, Andrea Pelosi, Piera Filomena Fiore, Nicola Tumino, Francesca Besi, Linda Quatrini, Silvia Santopolo, Paola Vacca, Lorenzo Moretta   +8 more
doaj   +1 more source

“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany [PDF]

Cancer Immunology, Immunotherapy, 2020
André Steven, Barbara Seliger
exaly   +2 more sources

Exosome‐mediated regulation of tumor immunology [PDF]

Cancer Science, 2018
Naohiro Seo, Kazunari Akiyoshi, Hiroshi Shiku   +2 more
exaly   +2 more sources

IX Forum on Translational Immunology and Cancer Immuno-therapy (FIT Cancer 9)

OncoImmunology, 2023
/INTRODUCTIONTumor immunology and cancer immunotherapy is a growing field, continuously evolving. Different types of immunotherapies have been implemented over last decade in the standard of care across several tumor types.
doaj   +1 more source

Mesenchymal stem cell therapy for liver disease: full of chances and challenges

Cell & Bioscience, 2020
Liver disease is a major health problem that endangers human health worldwide. Currently, whole organ allograft transplantation is the gold standard for the treatment of end-stage liver disease.
Xue Yang, Yan Meng, Zhipeng Han, Fei Ye, Lixin Wei, Chen Zong   +5 more
doaj   +1 more source

Transcription factors in fibroblast plasticity and CAF heterogeneity

Journal of Experimental & Clinical Cancer Research, 2023
In recent years, research focused on the multifaceted landscape and functions of cancer-associated fibroblasts (CAFs) aimed to reveal their heterogeneity and identify commonalities across diverse tumors for more effective therapeutic targeting of pro ...
Roberta Melchionna, Paola Trono, Anna Di Carlo, Francesca Di Modugno, Paola Nisticò   +4 more
doaj   +1 more source

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer

Cancer Cell International, 2023
Background Lack of Schlafen family member 11 (SLFN11) expression has been recently identified as a dominant genomic determinant of response to DNA damaging agents in numerous cancer types.
Christophe Michel Raynaud, Eiman I. Ahmed, Ayesha Jabeen, Apryl Sanchez, Shimaa Sherif, Tatiana C. Carneiro-Lobo, Amany Awad, Dina Awartani, Adviti Naik, Remy Thomas, Julie Decock, Gabriele Zoppoli, Davide Bedongnetti, Wouter R. L. Hendrickx   +13 more
doaj   +1 more source

A review on tumor immunology

Journal of Orofacial Sciences, 2017
The ability of immune system to detect and destroy the altered/abnormal cells may inhibit the development of various cancers. The immune system had been proposed as a tactic in sustaining nonneoplastic state and also for the development of immunotherapy ...
Sri Lalitha Kaja, S. V. N. Sasi Kiran, Kiran Kumar Kattapagari, Ravi Teja Chitturi, S Deepika Chowdary, Baddam Venkata Ramana Reddy   +5 more
doaj   +1 more source

Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling

OncoImmunology, 2022
While regulatory T cells (Tregs) and macrophages have been recognized as key orchestrators of cancer-associated immunosuppression, their cellular crosstalk within tumors has been poorly characterized.
Kevin Kos, Camilla Salvagno, Max D. Wellenstein, Muhammad A. Aslam, Denize A. Meijer, Cheei-Sing Hau, Kim Vrijland, Daphne Kaldenbach, Elisabeth A.M. Raeven, Martina Schmittnaegel, Carola H. Ries, Karin E. de Visser   +11 more
doaj   +1 more source

Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites

Bio-Protocol, 2017
Ovarian cancer is one of the most fatal tumors in women. Due to a lack of symptoms and adequate screening methods, patients are diagnosed at advanced stages with extensive tumor burden (Jelovac and Armstrong, 2011).
Christina Wefers, Ghaith Bakdash, Meritxell Moreno Martin, Tjitske Duiveman-de Boer, Ruurd Torensma, Leon Massuger, I Jolanda de Vries   +6 more
doaj   +1 more source